Open Phase 1 and 2 Cancer Clinical Trials

Trial #
Title
Description
Sponsor
Status
Investigator

ADVL1212

Crizotinib and Combination Chemotherapy in Treating Younger Patients with Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

This phase I trial studies the side effects and the best dose of crizotinib, given together with combination chemotherapy in treating younger patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma.

Children's Oncology Group

Currently enrolling

Jeffrey Dome, M.D.

ADVL1312

WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors

This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have not responded to standard therapy.

National Cancer Institute (NCI)

Currently enrolling

Jeffrey Dome, M.D.

ADVL1411

Talazoparib and Temozolomide in Treating Younger Patients with Refractory or Recurrent Malignancies

This phase I/II trial studies the side effects and best dose of talazoparib and temozolomide and to see how well they work in treating younger patients with tumors that have not responded to previous treatment (refractory) or have come back (recurrent).

National Cancer Institute (NCI)

Currently enrolling

Jeffrey Dome, M.D.

ADVL1412

Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas

This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory).

National Cancer Institute (NCI)

Currently enrolling

Jeffrey Dome, M.D.

ADVL1414

Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas

This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or high-grade gliomas that have come back (recurred) or do not respond to treatment (refractory).

Children's Oncology Group

Ongoing, not currently recruiting participants

Jeffrey Dome, M.D.

ADVL1416

A Study of Ramucirumab (LY3009806) in Children with Refractory Solid Tumors

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors, including central nervous system (CNS) tumors.

Eli Lilly and Company

Currently enrolling

AeRang Kim, M.D.

ADVL1513

Entinostat in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors

This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.

National Cancer Institute (NCI)

Currently enrolling

AeRang Kim, M.D.

ADVL1515

Prexasertib in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors

This phase I trial studies the side effects and best dose of prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or does not respond to treatment.

Children's Oncology Group

Currently enrolling

AeRang Kim, M.D.

ADVL1514

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors

This phase I trial studies the side effects and best dose of nanoparticle albumin-bound rapamycin when given together with temozolomide and irinotecan hydrochloride in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or has not responded to treatment.

Children's Oncology Group

Not yet open for recruitment

AeRang Kim, M.D.

ADVL1322

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

The purpose of this study is to find out what effects, good or bad, pazopanib (GW786034), National Service Center (NSC) # 737754, has on children, adolescents and young adults between 12 months and less than or equal to 18 years of age with relapsed or refractory rhabdomyosarcoma, non rhabdomyosarcomatous soft tissue sarcoma, Ewing sarcoma, relapsed or refractory osteosarcoma, neuroblastoma (measurable and/or evaluable) or hepatoblastoma.

Novartis Pharmaceuticals

Currently enrolling

AeRang Kim, M.D.

ADVL1621

A Study of Pembrolizumab (MK-3475) in Pediatric Participants with Advanced Melanoma or Advanced, Relapsed or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)

This is a two-part study of pembrolizumab (MK-3475) in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed or refractory solid tumor or other lymphoma.

Merck Sharp & Dohme Corp.

Currently enrolling

AeRang Kim, M.D.

ADVL1622

Cabozantinib-S-Malate in Treating Younger Patients with Recurrent, Refractory or Newly Diagnosed Sarcomas, Wilms Tumor or Other Rare Tumors

This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor or other rare tumors that have come back, do not respond to therapy or are newly diagnosed.

National Cancer Institute (NCI)

Currently enrolling

AeRang Kim, M.D.

NCT02076906

Safety and Feasibility Study of Using MR-guided High Intensity Focused Ultrasound for the Ablation of Relapsed or Refractory Pediatric Solid Tumors

Magnetic Resonance (MR)-guided high intensity focused ultrasound (HIFU) is an innovative technique that allows for non-invasive thermal ablation of tissue. Advantages over conventional local tumor control such as surgery, radiation, or radiofrequency are that MR-HIFU is completely non-invasive, non-ionizing and enables ablation of large tumor volumes with avoidance of adjacent tissue injury. This study will evaluate the safety and feasibility of MR-HIFU ablative therapy in children and young adults with refractory or relapsed solid tumors that are located in bone or soft tissue in close proximity to bone.

Children's National Health System

Currently enrolling

AeRang Kim, M.D.

NCT02536183

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound for Relapsed or Refractory Solid Tumors in Children, Adolescents and Young Adults

This study is looking to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lyso-thermosensitive liposomal doxorubicin (LTLD), a heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, administered in combination with MR-HIFU in children with relapsed/refractory solid tumors.

Children's National Health System

Currently enrolling

AeRang Kim, M.D.

NCT02677116

A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors

The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has two parts. In each part, a specific dose of olaratumab will be given for 21 days, followed by one of three standard chemotherapy regimens.

Eli Lilly and Company

Currently enrolling

AeRang Kim, M.D.